Globus Medical (GMED) Stock Still Looks Cheap As Its 3 Year Gain Hits 50%

Globus Medical shares have climbed over the past three years, yet recent setbacks on shorter time frames raise a basic question for you as an investor. Is the current US$74.52 price still in line with what the company is earning today and is expected to earn in the future?

• The stock has returned 50.1% over the past three years, which puts real weight on whether that share price still lines up with its earnings power.
• The business relies on converting orthopedic and spine procedures into consistent profit. Any shift in pricing, product mix or operating costs can change how comfortably its earnings support the current valuation.
• There is a second opinion on Globus Medical worth weighing. See what analysts think Globus Medical's shares could be worth.

The issue now is whether Globus Medical's earnings are strong and dependable enough to justify where the stock trades today.

If you want more context on whether Globus Medical's earnings profile and recent 3 year return of 50.1% feel reasonable, it can help to compare it with 32 high quality undervalued stocks.

Is Globus Medical a Bargain on Earnings?

The P/E ratio works well for Globus Medical because the market is clearly focused on what each dollar of earnings is worth today. At the current share price, the stock trades on roughly 18.7x earnings, which is below the broader Medical Equipment industry average of about 25.2x and well under the peer group closer to 37.6x.

The Fair Ratio model, which adjusts for Globus Medical's own margins, size and risk profile rather than just industry norms, implies a higher P/E than where the shares trade now. That places the current 18.7x multiple on the cheaper side of what this framework suggests could be reasonable, so the question for you is whether the earnings quality and growth path justify that kind of discount. Explore the numbers behind Globus Medical's P/E valuation.

The Globus Medical Narrative: What Would Justify Today's Price?

Narratives on Globus Medical pick up where the valuation puzzle leaves off and spell out which future paths for growth, margins and earnings would need to play out for the shares to look materially higher or lower than today’s price. Each one treats fair value as a thesis about how Globus Medical’s business could evolve over time, so you can watch how that idea holds up as new information comes through.

One of the top community narratives on Globus Medical: 28% undervalued

"Growing deployment of the Excelsius ecosystem, including a 25% year over year increase in EGPS and eHub units alongside more flexible lease and rental models..."

Discover why this Narrative puts Globus Medical at 28% undervalued.

For Globus Medical, the share price is only one piece of the decision

Before you decide how Globus Medical fits into your portfolio, it helps to look at who is steering the business, how their incentives are set and whether those rewards truly align with your interests. See who runs Globus Medical and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com